Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

Autor: Yong Huo, Martin C. Michel, Hans R. Brunner, Carolyn Foster
Rok vydání: 2016
Předmět:
0301 basic medicine
Blood Pressure
030204 cardiovascular system & hematology
Kidney
urologic and male genital diseases
Benzoates
Animals
Genetically Modified
Renin-Angiotensin System
Gene Knockout Techniques
0302 clinical medicine
Azilsartan
Pharmacology (medical)
Telmisartan
Oxadiazoles
biology
Stroke
medicine.anatomical_structure
Cardiovascular Diseases
Hypertension
Drug Therapy
Combination
medicine.drug
medicine.medical_specialty
03 medical and health sciences
Metabolic Diseases
Culture Techniques
Internal medicine
Renin–angiotensin system
medicine
Animals
Humans
Antihypertensive Agents
Pharmacology
Angiotensin II receptor type 1
business.industry
Angiotensin-converting enzyme
Atherosclerosis
Lipid Metabolism
medicine.disease
Disease Models
Animal
Glucose
030104 developmental biology
Blood pressure
Endocrinology
Pathophysiology of hypertension
biology.protein
Benzimidazoles
Endothelium
Vascular
business
Angiotensin II Type 1 Receptor Blockers
Zdroj: Pharmacology & Therapeutics. 164:1-81
ISSN: 0163-7258
Popis: We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after discontinuation of treatment. This translates into a reduced mortality, particularly in models exhibiting marked hypertension. The retrieved data on vascular, cardiac and renal function and morphology as well as on glucose and lipid metabolism are discussed to address three main questions: 1. Can ARB effects on blood vessels, heart, kidney and metabolic function be explained by blood pressure lowering alone or are they additionally directly related to blockade of the renin–angiotensin system? 2. Are they shared by other inhibitors of the renin–angiotensin system, e.g. angiotensin converting enzyme inhibitors? 3. Are some effects specific for one or more compounds within the ARB class? Taken together these data profile ARBs as a drug class with unique properties that have beneficial effects far beyond those on blood pressure reduction and, in some cases distinct from those of angiotensin converting enzyme inhibitors. The clinical relevance of angiotensin receptor-independent effects of some ARBs remains to be determined.
Databáze: OpenAIRE
Externí odkaz: